PL 102
Alternative Names: PL102Latest Information Update: 28 Aug 2020
At a glance
- Originator Polyrizon
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Allergic rhinitis; Tree pollen hypersensitivity
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Allergic-rhinitis in Israel (Intranasal, Spray)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Tree pollen hypersensitivity in Israel (Intranasal, Spray)